None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: • aged = 19 years old • histologically confirmed stage I~III breast cancer • completed neoadjuvant or adjuvant taxane-based chemotherapy • the average severity of CIPN is moderate to severe (NRS ?4) • started standard treatment (Duloxetine) for CIPN within a month. • ECOG ?3 • life expenctancy more than six months • signed informed consent
Exclusion criteria
Exclusion criteria: • receiving chemotherapy. • diagnosed with diabetic neuropathy. • diagnosed with neuropathy from any type of nerve compression • suspected alcohol or drug abuse • having received acupuncture treatment in the past one month • severe hemorrhagic coagulopathy or bleeding tendency. • pregnant, lactating, or planning to be pregnant • any other condition that the researcher considers to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BPI-SF average pain severity | — |
Secondary
| Measure | Time frame |
|---|---|
| BPI-SF average pain severity;Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (FACT/GOC-NTX);Beck Depression Inventory-II (BDI-II);Brief Fatigue Inventory (BFI) | — |
Countries
Korea, Republic of
Contacts
Kyung Hee University Oriental Medicine Hospital at Gangdong